All News
Banik et al. MTX as induction and maintenance for localised GPA. 48% in remission at 1 year. 39% required RTX. @RheumNow #ACR22 Abstr#1082 https://t.co/Pn8owLgaTj https://t.co/0iEeNuY2JU
Richard Conway RichardPAConway ( View Tweet)
Abstr #0732 utilized #NLP to capture and classify VZV infxn using 2 approaches
1. Bag of Words (BOW) - filtered by vaccine mentions
2. kNN- active vs historical infection
- BoW --> 92% accuracy
- kNN --> 64% accuracy
@RheumNow #ACR22 #NLP
Akhil Sood MD AkhilSoodMD ( View Tweet)
#abst1007 #acr22 We are what we eat. DIPSA RCT of Mediterranean diet& DASH-low caloric diet vs. standard of care as adjunct therapy in PsA w/BMI >25: low sugar & more whole fruit=⬇️PASI&SJC. ⬆️unsaturated than saturated fatty acids= higher enthesitis score. #acrbest @RheumNow https://t.co/cMKdlnJPQc
Olga Petryna DrPetryna ( View Tweet)
Roccatello et al. AAV with severe AKI. RTX+CYC+methylpred+no maintenance vs CYC+AZA maintenance. No difference in overall survival, 6-month therapeutic response rate, and 6-, and 12-month functional renal recovery. @RheumNow #ACR22 Abstr#1083 https://t.co/yv12bzwq6x https://t.co/YXUjpSzZ6I
Richard Conway RichardPAConway ( View Tweet)
#abst1012 #acr22 @rheumnow CASIPSA Study of SI CT in 48 PsA pts vs 48 controls. Disease duration 22.87 ± 14.95 y, 43.48 %HLA-B27+. higher prevalences of erosion in PsA (18%) preferentially located on the anterior and middle regions of the SIJs https://t.co/4dtJNCKf4I
Olga Petryna DrPetryna ( View Tweet)
axPsA and AS adult pts exhibit different genetic risk factors & serum IL-17 levels. GUS demonstrated significant pharmacodynamic effects and clinical improvement in axPsA and non-axPsA pts. Abs 1038 #ACR22 @RheumNow https://t.co/9Rjw7usO8J
Dr. Rachel Tate uptoTate ( View Tweet)
Updates on Reproductive Health in Women with SLE
https://t.co/E09cvQbVoD
#ACR22 https://t.co/Ausa6ELoHe
Links:
Dr. John Cush RheumNow ( View Tweet)
Dallas Heart Study: at least 1 aPL detected in 15% of adults from the general population. IgA isotypes of aCL & aβ2GPI independently assoc'd w/ future ASCVD events, and aβ2GPI IgA demonstrated increased risk of atherothrombosis. Abs 0681 #ACR22 @RheumNow https://t.co/m9XUTz2S5e https://t.co/vCXLJdBg70
Dr. Rachel Tate uptoTate ( View Tweet)
We know depression, anxiety are issues for many RA pts. Are we making the diagnosis more?
Olmsted County data:
depression similar over time
anxiety 3x more common in 2005-2014 vs 1985-1994 (adj age/sex +/- others)
How do we address this?
ABST0886 @MayoClinic #ACR22 @RheumNow https://t.co/tzMEE24FZo
David Liew drdavidliew ( View Tweet)
Molina et al. Dupilumab (IL4/IL13 mab) in refractory EGPA. Complete response 49%, partial 43%. But flares in 27%. Dupilumab-induced eosinophilia in 57%. @RheumNow #ACR22 Abstr#1074 https://t.co/cziyHNPN3j https://t.co/h7gWAShQeL
Richard Conway RichardPAConway ( View Tweet)
Zuo @jasonsknight et al. Dallas Heart Study. aPL and incident CV events. IgA isotypes of aCLand aβ2GPI were independently associated with future ASCVD events. @rheumnow #ACR22 Abstr#0681 https://t.co/C7O4rnFZCG https://t.co/1H7uiPUwuv
Richard Conway RichardPAConway ( View Tweet)
Abs 0674 finds that HIT is rare among hospitalized APS and SLE patients with aPL and that anti-PF4 antibodies are often inappropriately tested in this population. #ACR22 @RheumNow https://t.co/hFZzpuEkDG https://t.co/hyUYVZLUM4
Dr. Rachel Tate uptoTate ( View Tweet)
🔥 VEXAS + the 🫁 🔥
🔑 Points ~
🫁 involvement common
👉cough + dyspnea
🌬PFTS often normal
🩻 CXR useful but HRCT superior
🩻ground glass opacity commonest finding
💊 good response GC
🔥ignite session🔥
#ACR22
Abst# 1569 @RheumNow
Patricia Harkins DrTrishHarkins ( View Tweet)
Abs 0345 finds association between cumulated HCQ and development of cardiac abnormalities. We need further data to determine clinical association. #ACR22 @RheumNow https://t.co/WmixbFIlfd https://t.co/2Ejwkeu1Az
Dr. Rachel Tate uptoTate ( View Tweet)
In the absence of other high risk factor for thrombosis, Thrombocytopenia (ITP) could be an independent and long-lasting clinical phenotype for aPLs carriers. Abs 0672 #ACR22 @RheumNow https://t.co/LmlruGqkEJ https://t.co/MaIHS0QWN0
Dr. Rachel Tate uptoTate ( View Tweet)
Sometimes we guess how RA pts will be, before they come in.
machine learning to predict RA dx activity:
RISE registry (n=39,155)
inputs: prev CDAI, demo, smoking/obesity, SES
v good performance
Past performance does predict future outcomes, sometimes!
ABST0905 #ACR22 @RheumNow https://t.co/Ir1YG1cqlD
David Liew drdavidliew ( View Tweet)
Kajiyama et al. JAKi counteract cellular toxicity of HCQ in vitro. Could they prevent HCQ-retinopathy? @rheumnow #ACR22 Abstr#0653 https://t.co/c0a4OYCzw5 https://t.co/X7pFM7j1R4
Richard Conway RichardPAConway ( View Tweet)
RheumNow’s expanded coverage of the #ACR22 meeting is sponsored in part by Bristol-Myers Squibb. All content chosen by RheumNow & its Faculty
Dr. John Cush RheumNow ( View Tweet)
Park et al. Risk-benefit of PJP propylaxis in rituximab treated patients. NNH 86 . NNT - all RTX 146, RTX+high dose steroid 21. This mirrors my practice @RheumNow #ACR22 Abstr#0720 https://t.co/JPtPCqah9R https://t.co/bonRzWFbVw
Richard Conway RichardPAConway ( View Tweet)
Kaneko et al. Tocilizumab leads to significantly lower steroid doses in Adult onset Stills Disease @RheumNow #ACR22 Abstr#0826 https://t.co/jc1S6sdfkm https://t.co/z0cHB4wYu6
Richard Conway RichardPAConway ( View Tweet)